SUNNYVALE, Calif., Jan. 13, 2020 /PRNewswire/ -- Accuray
Incorporated (Nasdaq: ARAY) will be discussing its
business and revenue growth expectations for the next three fiscal
years at the JP Morgan Healthcare Conference on Wednesday, January 15, 2020 at 10:00 am PACIFIC / 1:00
pm EASTERN.
Josh Levine, president and chief
executive officer, said, "We are excited to be presenting at the JP
Morgan Healthcare Conference this week to discuss our line of sight
to sustainable revenue growth in the coming years. We expect our
growth catalysts in China,
including the recent grants of 50 out of 58 Type A radiotherapy
licenses to Accuray systems by the China Ministry of Health this
past October, along with our highly differentiated joint venture
strategy, will enable us to achieve compounded annual revenue
growth rate in the range of 8% to 12% from Fiscal 2021 through
Fiscal 2023. In addition, we expect these revenue growth rates will
drive faster expansion in our operating income and adjusted EBITDA
for the same periods."
The presentation to be delivered at the JP Morgan Healthcare
Conference can be accessed on the Accuray website at
www.accuray.com/investors.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter
and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to revenue growth expectations
for the next three fiscal years, expectations regarding operating
income and adjusted EBITDA, growth drivers, and Accuray's
leadership position in radiation oncology innovation and
technologies. These forward-looking statements involve risks and
uncertainties. If any of these risks or uncertainties materialize,
or if any of the company's assumptions prove incorrect, actual
results could differ materially from the results expressed or
implied by these forward-looking statements. These risks and
uncertainties include, but are not limited to, the company's
ability to achieve widespread market acceptance of its products;
the company's ability to effectively integrate and execute the
joint venture; the company's ability to realize the expected
benefits of the joint venture; risks and uncertainties related to
future Type A and B license announcements in China; risks inherent in international
operations; the company's ability to effectively manage its growth;
the company's ability to convert backlog into revenue; and such
other risks identified under the heading "Risk Factors" in the
company's quarterly report on Form 10-Q, filed with the Securities
and Exchange Commission (the "SEC") on November 6, 2019 and as updated periodically with
the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future
events. The company assumes no obligation to update
forward-looking statements to reflect actual performance or
results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent
required by applicable securities laws. Accordingly, investors
should not put undue reliance on any forward-looking
statements.
Investor Contacts
Lytham Partners
Joe Diaz, Joe Dorame or Robert
Blum
+1 (602) 889-9700
aray@lythampartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accuray-to-discuss-revenue-growth-expectations-for-the-next-three-fiscal-years-at-the-jp-morgan-healthcare-conference-300985404.html
SOURCE Accuray Incorporated